EXPLORE CONNECTIONS
Safety, pharmacokinetics and pharmacodynamics of TQC3721, an innovative, dual PDE3 and PDE4 inhibitor, in healthy subjects and patients with chronic obstructive pulmonary disease: Randomised, double-blind, placebo-controlled phase I and IIa clinical trials.
Follow the relationships that help you find your next source.
Connections are not prepared for this record yet, or its source metadata has changed. The original record remains available while background snapshots are rebuilt.